Rexahn Pharmaceuticals, Inc. (REXN)
REXN Stock Price Chart
Key Info
| Market Cap | 2.03M |
| Revenue (ttm) | 1.15M |
| Net Income (ttm) | -6.37M |
| Shares Out | 4.24M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Nov 5, 2020 |
| Last Price | $1.81 |
| Previous Close | $1.87 |
| Change ($) | -0.06 |
| Change (%) | -3.21% |
| Day's Open | - |
| Day's Range | 1.72 - 1.93 |
| Day's Volume | 0 |
| 52-Week Range | 1.70 - 3.70 |
REXN Stock News
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is ...
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Re...
NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphir...
New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (...
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates
About REXN
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang ... [Read more...]
| Industry Biotechnology | |
| CEO Douglas J. Swirsky | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol REXN |